Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Can BELBUCA become the standard of care? How important is the Schedule 3 designation vs. other pain killers both for patients' health and prescribing?

Ticker(s): BDSI, TEVA, PFE, PTX, ENDP, Purdue Pharma

Who's the expert?

Name: Dr Richard Boortz-Marx - MD

Institution: Duke University

  • Associate Professor of Anesthesiology and Director of Interventional Pain.
  • Extensive research experience performing both investigator-initiated and industry sponsored studies, has led two clinical trials that examined the efficacy of pain medicine in surgical and non-surgical patient.
  • Expert on current standards for opioid management; has authored numerous articles in peer reviewed journals.

Interview Questions
Q1.

Please describe your pain management practice, specifically how many patients you treat and how you typically treat them.

Added By: joe_mccann
Q2.

How significant a concern is opioid dependence in your practice on a day to day basis vs. the significant media/political headlines we see on the topic?

Added By: joe_mccann
Q3.

Can you please describe your impression of the BELBUCA label? We can get into details, but specifically the efficacy and how it compares to your current options.

Added By: joe_mccann
Q4.

How do you see BELBUCA being viewed at insurers vs. cheap generic opioids?

Added By: joe_mccann
Q5.

Can you please describe how you see BELBUCA's profile vs. ER Opioids when it comes to abuse and risk of developing addiction? From a practical/ clinical perspective vs. theoretical?

Added By: joe_mccann
Q6.

What percent of your patients do you see prescribing BELBUCA if initial patient experience is in line with the expectations you described?

Added By: joe_mccann
Q7.

Will the recent guidelines from the CDC encourage you to alter your prescribing habits? What percentage of your current patients would you consider switching from existing therapies to Belbuca?

Added By: c_admin
Q8.

Do you think the changes in the CDC guidelines will drive lawsuits against doctors that do not follow them? Do you think that doctors will follow the guidelines for fear of lawsuits very quickly?

Added By: c_admin

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.